MERCK & CO., INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
+2.60% | -.--% |
| May. 23 | HPV vaccine provides real benefits for men, analysis shows | RE |
| May. 15 | Transcript : Merck & Co., Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM |
Business Summary
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sales per Business
| USD in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Pharmaceutical
89.1
%
| 52,005 | 87.7 % | 53,583 | 89.1 % | +3.03% |
Animal Health
9.4
%
| 5,550 | 9.4 % | 5,625 | 9.4 % | +1.35% |
Other
1.5
%
| 1,728 | 2.9 % | 907 | 1.5 % | -47.51% |
Sales per region
| USD in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
United States
47.4
%
| 27,206 | 45.9 % | 28,480 | 47.4 % | +4.68% |
Europe, Middle East and Africa
22.0
%
| 14,493 | 24.4 % | 13,254 | 22.0 % | -8.55% |
China
11.3
%
| 5,191 | 8.8 % | 6,802 | 11.3 % | +31.03% |
Asia Pacific
5.4
%
| 3,614 | 6.1 % | 3,225 | 5.4 % | -10.76% |
Japan
5.3
%
| 3,629 | 6.1 % | 3,164 | 5.3 % | -12.81% |
Latin America
5.1
%
| 2,582 | 4.4 % | 3,086 | 5.1 % | +19.52% |
Other
3.5
%
| 2,568 | 4.3 % | 2,104 | 3.5 % | -18.07% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Joseph Romanelli
IRC | Investor Relations Contact | 50 | 95-12-31 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 17-06-30 |
Andre Musto
PRN | Corporate Officer/Principal | - | 14-06-30 |
Brooke Hinkson
PRN | Corporate Officer/Principal | - | 15-07-31 |
Carol Bowden
PRN | Corporate Officer/Principal | - | 14-03-31 |
Dalton Smart
AUD | Comptroller/Controller/Auditor | 58 | 09-10-31 |
James Matteucci
PRN | Corporate Officer/Principal | - | 02-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
Patricia Russo
BRD | Director/Board Member | 71 | 95-08-31 |
Peter Wendell
BRD | Director/Board Member | 73 | 03-09-22 |
| Director/Board Member | 69 | 20-05-25 | |
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Douglas Baker
BRD | Director/Board Member | 65 | 22-05-23 |
Stephen Mayo
BRD | Director/Board Member | 62 | 21-03-14 |
Kathy Warden
BRD | Director/Board Member | 52 | 20-03-15 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 3,577,208,962 | 2,531,418,332 ( 70.77 %) | 1,044,402,655 ( 29.20 %) | 70.77 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
| 13,443,693 | 10.62% | 289,287,301 $ | |
| 1,739,768 | 5.17% | 21,503,532 $ | |
XILIO THERAPEUTICS, INC. 4.02% | 1,483,414 | 4.02% | 1,498,248 $ |
EVAXION BIOTECH A/S 12.13% | 2,297,884 | 12.13% | 946,728 $ |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
MSD Regional Business Support Center GmbH
 MSD Regional Business Support Center GmbH Miscellaneous Commercial ServicesCommercial Services Part of Merck & Co., Inc., MSD Regional Business Support Center GmbH is a German company that provides management consulting services. The company is based in Munich, Germany. Jutta König has been the CEO of the company since 2021. |
Miscellaneous Commercial Services
|
Merck Holdings, Inc.
| |
MSD International GmbH (Switzerland)
 MSD International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD International GmbH (Switzerland) is a Swiss company that discovers, develops and markets human and animal health products. The company is located in Switzerland. |
Pharmaceuticals: Major
|
Schering Plough International Finance Co. BV
| |
MSD Human Health Holding BV
 MSD Human Health Holding BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD Human Health Holding BV discovers, develops and markets human and animal health products. The company is based in Oss, Netherlands. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme LLC
 Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme LLC is a pharmaceutical company. The company is based in Kenilworth, NJ. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme Corp.
 Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. |
Pharmaceuticals: Major
|
Essex Chemie AG
| |
Merck Sharp & Dohme BV
 Merck Sharp & Dohme BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme BV is a Dutch company that manufactures and distributes pharmaceutical products. The company is based in Haarlem, the Netherlands. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B | |
| +0.31% | 164B |
- Stock Market
- Equities
- MRK Stock
- 0QAH Stock
- Company Merck & Co., Inc.
